Genovis has entered into a license agreement with Life Technologies a wholly

owned subsidiary of Thermo Fisher Scientific and is launching a unique new

technology for labeling antibodies. The first product, GlyCLICK™, will be

launched in the autumn.

Labeling of antibodies includes several elements in the chain from development,

preclinical, diagnostic and therapeutic applications in the pharmaceutical industry. By

combining Genovis’ unique enzymes with SiteClick™ technology from Life

Technologies antibodies will be labeled precisely and completely at the same site

each time, regardless of the type of antibody or its origin. Genovis will focus sales and

marketing resources for GlyCLICK on the preclinical market in the biopharma industry

where the company already has the majority of its customer base. Initially, the

technology will be marketed in the market for preclinical imaging. The reagent market

for this segment